Use of neurally adjusted ventilatory assist (NAVA) in a patient with severe SARS-CoV-2 pneumonia: A case report

Abstract

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia may necessitate intubation and prolonged mechanical ventilation. Early in the course of mechanical ventilation neuromuscular blocking agents may be used to allow synchronous lung protective ventilation. However, patients with SARS-CoV-2 pneumonia tend to have an intense respiratory drive resulting in patient–ventilator asynchrony when neuromuscular blocking agents are discontinued. Case and Outcomes A 75-year-old male was admitted to the hospital with SARS-CoV-2 pneumonia requiring invasive mechanical ventilation. By ventilator day 5 the neuromuscular blocking agent had been discontinued, and the patient was markedly asynchronous in the volume control mode despite receiving continuous intravenous sedatives. The ventilator mode was changed to the neurally adjusted ventilatory assist (NAVA) mode. Initially NAVA resulted in improved synchrony and reduced work of breathing. However, a few days later the patient’s tidal volume had fallen to <300 mL on NAVA despite increases in the NAVA level. It appeared that the inspiratory phase was prematurely terminating, and the expiratory threshold in NAVA is not adjustable. The ventilator mode was changed to pressure support resulting in an increased tidal volume and reduced respiratory frequency. Conclusion In patients with SARS-CoV-2 pneumonia and intense respiratory drive, the performance of NAVA may be variable. NAVA may result in hypopnea and tachypnea when compared with pressure support. An assessment of the impact of an adjustable expiratory threshold in NAVA is warranted.